Clinical Trial Imaging Market by Software & Service (Operational Imaging, Trial Design), Modality (CT, MRI, X-Ray, PET, Ultrasound), Therapeutic Area (Infectious, Oncology, CNS, CVD), End User (Pharma, Biotech, CROs) - Global Forecast to 2029
According to projections, the global clinical trial imaging market is expected to grow at a compound annual growth rate (CAGR) of 7.8%, from USD 1.42 billion in 2024 to USD 2.07 billion by 2029. Factors driving the market's growth include the biotechnology and pharmaceutical industries' expansion, the rise in R&D spending, and the number of Contract Research Organizations (CROs). However, the primary factors impeding the market's growth during the projection period are the high cost of clinical trials and the high implementation cost of imaging systems.
“By service & software, the service sector had the fastest growth rate in the clinical trial imaging market throughout the projected period.”
Based on type, services and software comprise the clinical trial imaging industry. In the clinical trial imaging market in 2023, the service sector had the fastest growth rate. The operational imaging services, reader analysis services, system & technical support services, and trial design consulting services are further subdivided under the services sector based on type. Growing R&D expenditures, an increase in clinical trials, and the need for novel illness treatments and diagnostics are the main factors contributing to this segment's growth.
“Medical device manufacturers segment accounted for the highest CAGR.”
The pharmaceutical and biotechnology firms, medical device manufacturers, contract research organizations, academic and government research institutes, and other end users are the segments of the clinical trial imaging market based on end user. The segment with the highest growth rate in 2023 was medical device manufacturers. This can be explained by the fact that the major growth drivers of the medical device manufacturers segment are the rising R&D expenditures and R&D activity by medical device manufacturers as well as the growing medical device market.
“Asia Pacific: The fastest-growing region clinical trial imaging market.”
The markets for clinical trial imaging across North America, Europe, Asia Pacific, Latin America, the Middle East and Africa and GCC countries comprise the global market. Over the course of the projection period, the Asia Pacific area is expected to record the greatest CAGR. The large number of SMEs, the presence of a large treatment-na?ve population for clinical trials, less-stringent regulations governing the use of animals in clinical research, the availability of local CROs with strong regulatory and linguistic understanding, the presence of highly qualified researchers, and the low cost of clinical trials are the major factors driving the R&D sector. These drivers driving the market's expansion are therefore due to the rise in R&D expenditures and the increasing trend of outsourcing pharmaceutical research to developing Asian countries.
The primary interviews conducted for this report can be categorized as follows:
Research Coverage:
This research report categorizes the clinical trial imaging market by service & software, modality, therapeutic area, end user and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the clinical trial imaging market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; Contracts, partnerships, agreements, new product & service launches, mergers and acquisitions, and recent developments associated with the clinical trial imaging market. Competitive analysis of upcoming startups in the clinical trial imaging market ecosystem is covered in this report.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall clinical trial imaging market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, challenges, and opportunities.
The report provides insights on the following pointers:
“By service & software, the service sector had the fastest growth rate in the clinical trial imaging market throughout the projected period.”
Based on type, services and software comprise the clinical trial imaging industry. In the clinical trial imaging market in 2023, the service sector had the fastest growth rate. The operational imaging services, reader analysis services, system & technical support services, and trial design consulting services are further subdivided under the services sector based on type. Growing R&D expenditures, an increase in clinical trials, and the need for novel illness treatments and diagnostics are the main factors contributing to this segment's growth.
“Medical device manufacturers segment accounted for the highest CAGR.”
The pharmaceutical and biotechnology firms, medical device manufacturers, contract research organizations, academic and government research institutes, and other end users are the segments of the clinical trial imaging market based on end user. The segment with the highest growth rate in 2023 was medical device manufacturers. This can be explained by the fact that the major growth drivers of the medical device manufacturers segment are the rising R&D expenditures and R&D activity by medical device manufacturers as well as the growing medical device market.
“Asia Pacific: The fastest-growing region clinical trial imaging market.”
The markets for clinical trial imaging across North America, Europe, Asia Pacific, Latin America, the Middle East and Africa and GCC countries comprise the global market. Over the course of the projection period, the Asia Pacific area is expected to record the greatest CAGR. The large number of SMEs, the presence of a large treatment-na?ve population for clinical trials, less-stringent regulations governing the use of animals in clinical research, the availability of local CROs with strong regulatory and linguistic understanding, the presence of highly qualified researchers, and the low cost of clinical trials are the major factors driving the R&D sector. These drivers driving the market's expansion are therefore due to the rise in R&D expenditures and the increasing trend of outsourcing pharmaceutical research to developing Asian countries.
The primary interviews conducted for this report can be categorized as follows:
- By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%
- By Designation: C-level - 27%, D-level - 18%, and Others - 55%
- By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America – 6%, and the Middle East & Africa – 4%
Research Coverage:
This research report categorizes the clinical trial imaging market by service & software, modality, therapeutic area, end user and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the clinical trial imaging market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; Contracts, partnerships, agreements, new product & service launches, mergers and acquisitions, and recent developments associated with the clinical trial imaging market. Competitive analysis of upcoming startups in the clinical trial imaging market ecosystem is covered in this report.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall clinical trial imaging market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, challenges, and opportunities.
The report provides insights on the following pointers:
- Analysis of key drivers, restraints, opportunities, and challenges influencing the growth of the clinical trial imaging market.
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the clinical trial imaging market.
- Market Development: Comprehensive information about lucrative markets – the report analyses the clinical trial imaging market across varied regions.
- Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the clinical trial imaging market.
- Competitive Assessment: In-depth assessment of market ranking, growth strategies and service offerings of leading players like ICON plc. (Ireland), BioTelemetry Inc. (US), Biomedical Systems Corporation (US), and Medpace Holdings, Inc. (US), among others in the clinical clinical trial imaging market strategies.
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 SEGMENTS CONSIDERED
1.3.2 INCLUSIONS AND EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.2 RESEARCH APPROACH
2.2.1 SECONDARY DATA
2.2.1.1 Key data from secondary sources
2.2.1.2 Objectives of secondary research
2.2.2 PRIMARY DATA
2.2.2.1 Objectives of primary research
2.2.2.2 Key data from primary sources
2.2.2.3 Key industry insights
2.2.2.4 Breakdown of primaries
2.3 MARKET SIZE ESTIMATION
2.3.1 BOTTOM-UP APPROACH
2.3.1.1 Company revenue estimation approach
2.3.1.2 Company presentations and primary interviews
2.3.1.3 Growth forecasts
2.3.1.4 CAGR projections
2.3.2 TOP-DOWN APPROACH
2.4 DATA TRIANGULATION
2.5 STUDY ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.7 RISK ASSESSMENT
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 CLINICAL TRIAL IMAGING MARKET OVERVIEW
4.2 CLINICAL TRIAL IMAGING MARKET SHARE, BY SERVICE & SOFTWARE, 2024 VS. 2029
4.3 CLINICAL TRIAL IMAGING MARKET SHARE, BY MODALITY, 2024 VS. 2029
4.4 CLINICAL TRIAL IMAGING MARKET SHARE, BY THERAPEUTIC AREA, 2024 VS. 2029
4.5 CLINICAL TRIAL IMAGING MARKET SHARE, BY END USER, 2024 VS. 2029
4.6 CLINICAL TRIAL IMAGING MARKET: REGIONAL GROWTH OPPORTUNITIES
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Increasing R&D spending in pharmaceutical and biotechnology companies
5.2.1.2 Rising number of clinical trials in medical research
5.2.1.3 Growth in pharmaceutical and biotechnology industries
5.2.1.4 Increasing number of contract research organizations
5.2.2 RESTRAINTS
5.2.2.1 High implementation cost of imaging systems
5.2.3 OPPORTUNITIES
5.2.3.1 Growth opportunities in emerging economies
5.2.3.2 Development of innovative imaging modalities, contrast agents, molecular probes, and radiopharmaceuticals
5.2.4 CHALLENGES
5.2.4.1 High cost of clinical trials
5.3 PRICING ANALYSIS
5.3.1 INDICATIVE PRICING ANALYSIS FOR CLINICAL TRIAL IMAGING SERVICES & SOFTWARE, 2021–2023
5.4 PATENT ANALYSIS
5.4.1 LIST OF MAJOR PATENTS, 2022–2023
5.5 TRADE ANALYSIS
5.5.1 TRADE ANALYSIS FOR X-RAY APPARATUS (HS CODE 9022)
5.5.1.1 Import data for X-ray apparatus
5.5.1.2 Export data for X-ray apparatus
5.5.2 TRADE ANALYSIS FOR CT APPARATUS (HS CODE 902212)
5.5.2.1 Import data for CT apparatus
5.5.2.2 Export data for CT apparatus
5.6 VALUE CHAIN ANALYSIS
5.7 SUPPLY CHAIN ANALYSIS
5.8 ECOSYSTEM ANALYSIS
5.8.1 ROLE IN ECOSYSTEM
5.9 PORTER’S FIVE FORCES ANALYSIS
5.9.1 THREAT OF NEW ENTRANTS
5.9.2 THREAT OF SUBSTITUTES
5.9.3 BARGAINING POWER OF BUYERS
5.9.4 BARGAINING POWER OF SUPPLIERS
5.9.5 INTENSITY OF COMPETITIVE RIVALRY
5.10 KEY STAKEHOLDERS AND BUYING CRITERIA
5.10.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.10.2 KEY BUYING CRITERIA
5.11 REGULATORY ANALYSIS
5.11.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.12 KEY CONFERENCES AND EVENTS IN 2023–2024
5.13 TECHNOLOGY ANALYSIS
5.13.1 KEY TECHNOLOGIES
5.13.1.1 CT and MRI
5.13.2 COMPLEMENTARY TECHNOLOGIES
5.13.2.1 Ultrasound
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.15 CASE STUDY ANALYSIS
5.15.1 REVIEW OF CT FINDINGS AND HISTOPATHOLOGICAL CHARACTERISTICS OF PRIMARY LIVER CARCINOSARCOMA
5.16 IMPACT OF AI/GENERATIVE AI ON CLINICAL TRIAL IMAGING MARKET
6 CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE
6.1 INTRODUCTION
6.2 SERVICES
6.2.1 OPERATIONAL IMAGING SERVICES
6.2.1.1 Rising number of CROs and growing pharmaceutical industry to drive market
6.2.2 READ ANALYSIS SERVICES
6.2.2.1 Increasing number of clinical trials and rising R&D spending to support market growth
6.2.3 SYSTEM AND TECHNICAL SUPPORT SERVICES
6.2.3.1 Need for continuous technical support to propel segment growth
6.2.4 TRIAL DESIGN AND CONSULTING SERVICES
6.2.4.1 High R&D spending and favorable government initiatives for clinical trials to fuel market growth
6.3 SOFTWARE
6.3.1 NEED FOR HIGHLY EFFICIENT AND COST-EFFECTIVE CLINICAL OPERATIONS SOFTWARE TO FAVOR MARKET GROWTH
7 CLINICAL TRIAL IMAGING MARKET, BY MODALITY
7.1 INTRODUCTION
7.2 COMPUTED TOMOGRAPHY
7.2.1 HIGHER CONTRAST IMAGE AND QUICKER TEST RESULTS TO AUGMENT SEGMENT GROWTH
7.3 MAGNETIC RESONANCE IMAGING
7.3.1 GREATER OBJECTIVITY, SENSITIVITY, AND REPRODUCIBILITY TO PROPEL MARKET GROWTH
7.4 ULTRASOUND
7.4.1 COST-EFFECTIVENESS AND EASE OF USE TO FUEL MARKET GROWTH
7.5 POSITRON EMISSION TOMOGRAPHY
7.5.1 ABILITY TO ASSESS PHARMACOKINETIC AND PHARMACODYNAMIC EVENTS IN HUMANS AND ANIMALS TO BOOST MARKET GROWTH
7.6 X-RAY
7.6.1 LOW SCANNING COST AND TECHNOLOGICAL ADVANCEMENTS TO FAVOR MARKET GROWTH
7.7 OTHER MODALITIES
8 CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA
8.1 INTRODUCTION
8.2 ONCOLOGY
8.2.1 GROWING INCIDENCE OF CANCER AND INCREASING R&D INVESTMENTS BY PHARMA COMPANIES TO AID MARKET GROWTH
8.3 INFECTIOUS DISEASES
8.3.1 RISING DRUG DISCOVERY ACTIVITY AND GROWING DEMAND FOR THERAPEUTICS TO SPUR MARKET GROWTH
8.4 NEUROLOGY
8.4.1 HIGH RESEARCH INVESTMENTS FOR NEUROLOGIC DRUGS TO PROPEL MARKET GROWTH
8.5 CARDIOVASCULAR SYSTEM DISORDERS
8.5.1 HIGH MORTALITY RATE AND COMPLEX CLINICAL TRIAL PROCEDURES TO AUGMENT MARKET GROWTH
8.6 ENDOCRINOLOGY
8.6.1 RISING PREVALENCE OF DIABETES AND INCREASING RESEARCH FUNDING FOR METABOLIC DISORDERS TO DRIVE MARKET
8.7 IMMUNOLOGICAL DISORDERS
8.7.1 WIDE PREVALENCE OF ALLERGIES, ASTHMA, AND AUTOIMMUNE DISEASES TO SUPPORT MARKET GROWTH
8.8 OTHER THERAPEUTIC AREAS
9 CLINICAL TRIAL IMAGING MARKET, BY END USER
9.1 INTRODUCTION
9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
9.2.1 HIGH R&D BUDGETS AND FAVORABLE GOVERNMENT INITIATIVES TO SUPPORT MARKET GROWTH
9.3 MEDICAL DEVICE MANUFACTURERS
9.3.1 HIGH SPENDING ON R&D AND CLINICAL TRIALS TO SUPPORT MARKET GROWTH
9.4 CONTRACT RESEARCH ORGANIZATIONS
9.4.1 INCREASING TREND OF OUTSOURCING AND GROWING PATIENT POPULATION IN EMERGING ECONOMIES TO AID MARKET GROWTH
9.5 ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES
9.5.1 RISING RESEARCH FUNDING AND INCREASING GOVERNMENT SUPPORT FOR CLINICAL TRIALS TO BOOST MARKET GROWTH
9.6 OTHER END USERS
10 CLINICAL TRIAL IMAGING MARKET, BY REGION
10.1 INTRODUCTION
10.2 NORTH AMERICA
10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
10.2.2 US
10.2.2.1 US to dominate North American clinical trial imaging market during study period
10.2.3 CANADA
10.2.3.1 Increase in per capita healthcare spending to augment market growth
10.3 EUROPE
10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
10.3.2 GERMANY
10.3.2.1 Strong medical technology infrastructure and increased funding for biomedical research to augment market growth
10.3.3 UK
10.3.3.1 Increased R&D investments and high per capita healthcare expenditure to augment market growth
10.3.4 FRANCE
10.3.4.1 Developed generics market and favorable government healthcare policies to support market growth
10.3.5 ITALY
10.3.5.1 Increasing number of drug approvals and rising investments in clinical trials to drive market
10.3.6 SPAIN
10.3.6.1 Increased biologics production and improved healthcare infrastructure to aid market growth
10.3.7 REST OF EUROPE
10.4 ASIA PACIFIC
10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
10.4.2 CHINA
10.4.2.1 Favorable government regulations and presence of large target patient population to boost market growth
10.4.3 JAPAN
10.4.3.1 Increasing geriatric population and rising healthcare expenditure to favor market growth
10.4.4 INDIA
10.4.4.1 Increased government focus on developing advanced healthcare infrastructure to augment market growth
10.4.5 REST OF ASIA PACIFIC
10.5 LATIN AMERICA
10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
10.5.2 BRAZIL
10.5.2.1 Increasing investments in biopharmaceutical research to propel market growth
10.5.3 MEXICO
10.5.3.1 Developed pharmaceutical and biotechnology industry and high demand for personalized medicines to aid market growth
10.5.4 REST OF LATIN AMERICA
10.6 MIDDLE EAST & AFRICA
10.6.1 INCREASED FUNDING AND COLLABORATIONS IN RESEARCH SECTOR TO DRIVE MARKET
10.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
10.7 GCC COUNTRIES
10.7.1 INCREASING RESEARCH ACTIVITIES AND GROWING BIOTECHNOLOGY INDUSTRY TO SPUR MARKET GROWTH
10.7.2 MACROECONOMIC OUTLOOK FOR GCC COUNTRIES
11 COMPETITIVE LANDSCAPE
11.1 INTRODUCTION
11.2 KEY PLAYER STRATEGY/RIGHT TO WIN
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN CLINICAL TRIAL IMAGING MARKET
11.3 REVENUE ANALYSIS, 2021–2023
11.4 MARKET SHARE ANALYSIS, 2023
11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS (2023)
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE PLAYERS
11.5.4 PARTICIPANTS
11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
11.5.5.1 Company footprint
11.5.5.2 Service & software footprint
11.5.5.3 Therapeutic area footprint
11.5.5.4 Region footprint
11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
11.6.1 PROGRESSIVE COMPANIES
11.6.2 RESPONSIVE COMPANIES
11.6.3 DYNAMIC COMPANIES
11.6.4 STARTING BLOCKS
11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
11.7 COMPANY VALUATION AND FINANCIAL METRICS
11.8 COMPETITIVE SCENARIO
11.8.1 SERVICE AND SOLUTION LAUNCHES AND REGULATORY APPROVALS
11.8.2 DEALS
12 COMPANY PROFILES
12.1 KEY PLAYERS
12.1.1 ICON PLC
12.1.1.1 Business overview
12.1.1.2 Services/Solutions offered
12.1.1.3 Recent developments
12.1.1.3.1 Solution launches
12.1.1.3.2 Deals
12.1.1.4 MnM view
12.1.1.4.1 Key strengths
12.1.1.4.2 Strategic choices
12.1.1.4.3 Weaknesses and competitive threats
12.1.2 MEDPACE
12.1.2.1 Business overview
12.1.2.2 Services/Solutions offered
12.1.2.3 MnM view
12.1.2.3.1 Key strengths
12.1.2.3.2 Strategic choices
12.1.2.3.3 Weaknesses and competitive threats
12.1.3 CLARIO
12.1.3.1 Business overview
12.1.3.2 Services/Solutions offered
12.1.3.3 Recent developments
12.1.3.3.1 Solution launches
12.1.3.3.2 Deals
12.1.3.4 MnM view
12.1.3.4.1 Key strengths
12.1.3.4.2 Strategic choices
12.1.3.4.3 Weaknesses and competitive threats
12.1.4 IXICO PLC
12.1.4.1 Business overview
12.1.4.2 Services/Solutions offered
12.1.4.3 Recent developments
12.1.4.3.1 Deals
12.1.4.3.2 Other developments
12.1.5 RESONANCE HEALTH LTD.
12.1.5.1 Business overview
12.1.5.2 Services/Solutions offered
12.1.5.3 Recent developments
12.1.5.3.1 Service launches and regulatory approvals
12.1.5.3.2 Deals
12.1.6 RADIANT SAGE
12.1.6.1 Business overview
12.1.6.2 Services/Solutions offered
12.1.7 WCG CLINICAL
12.1.7.1 Business overview
12.1.7.2 Services/Solutions offered
12.1.7.3 Recent developments
12.1.7.3.1 Deals
12.1.8 CARDIOVASCULAR IMAGING TECHNOLOGIES
12.1.8.1 Business overview
12.1.8.2 Services/Solutions offered
12.2 OTHER PLAYERS
12.2.1 MEDICAL METRICS, INC.
12.2.2 PRISM CLINICAL IMAGING
12.2.3 BOSTON IMAGING CORE LAB
12.2.4 ANAGRAM 4 CLINICAL TRIALS
12.2.5 VOIANT
12.2.6 CALYX
12.2.7 BIOSPECTIVE INC.
12.2.8 PROSCAN IMAGING
12.2.9 MICRON, INC.
12.2.10 IMAGING ENDPOINTS
12.2.11 PERSPECTUM
12.2.12 PHARMTRACE
12.2.13 NAVITAS LIFE SCIENCES
12.2.14 MEDIAN TECHNOLOGIES
12.2.15 INVICRO, LLC
12.2.16 IMAGE CORE LAB
12.2.17 IMAGE ANALYSIS GROUP (IAG)
13 APPENDIX
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 CUSTOMIZATION OPTIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
TABLE 1 CLINICAL TRIAL IMAGING MARKET: INCLUSIONS AND EXCLUSIONS
TABLE 2 CLINICAL TRIAL IMAGING MARKET: KEY DATA FROM PRIMARY SOURCES
TABLE 3 CLINICAL TRIAL IMAGING MARKET: RISK ASSESSMENT ANALYSIS
TABLE 4 INDICATIVE SELLING PRICE TREND FOR CLINICAL TRIAL IMAGING SERVICES & SOFTWARE, 2021–2023
TABLE 5 CLINICAL TRIAL IMAGING MARKET: LIST OF KEY PATENTS,
JANUARY 2022–DECEMBER 2023
TABLE 6 IMPORT DATA FOR X-RAY APPARATUS (HS CODE 9022), BY COUNTRY,
2018–2022 (USD MILLION)
TABLE 7 EXPORT DATA FOR X-RAY APPARATUS (HS CODE 9022), BY COUNTRY,
2018–2022 (USD MILLION)
TABLE 8 IMPORT DATA FOR CT APPARATUS (HS CODE 902212), BY COUNTRY,
2018–2022 (USD MILLION)
TABLE 9 EXPORT DATA FOR CT APPARATUS (HS CODE 902212), BY COUNTRY,
2018–2022 (USD MILLION)
TABLE 10 CLINICAL TRIAL IMAGING MARKET: ROLE IN ECOSYSTEM
TABLE 11 CLINICAL TRIAL IMAGING MARKET: IMPACT OF PORTER’S FIVE FORCES
TABLE 12 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS
TABLE 13 KEY BUYING CRITERIA FOR MAJOR END USERS
TABLE 14 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS
TABLE 15 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 16 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS
TABLE 17 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS
TABLE 18 MIDDLE EAST & AFRICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 19 CLINICAL TRIAL IMAGING MARKET: DETAILED LIST OF KEY CONFERENCES AND EVENTS, JANUARY 2023–DECEMBER 2024
TABLE 20 CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE,
2022–2029 (USD MILLION)
TABLE 21 CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE,
2022–2029 (USD MILLION)
TABLE 22 CLINICAL TRIAL IMAGING SERVICES MARKET, BY REGION,
2022–2029 (USD MILLION)
TABLE 23 NORTH AMERICA: CLINICAL TRIAL IMAGING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 24 EUROPE: CLINICAL TRIAL IMAGING SERVICES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 25 ASIA PACIFIC: CLINICAL TRIAL IMAGING SERVICES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 26 LATIN AMERICA: CLINICAL TRIAL IMAGING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 27 OPERATIONAL IMAGING SERVICES MARKET, BY REGION,
2022–2029 (USD MILLION)
TABLE 28 NORTH AMERICA: OPERATIONAL IMAGING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 29 EUROPE: OPERATIONAL IMAGING SERVICES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 30 ASIA PACIFIC: OPERATIONAL IMAGING SERVICES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 31 LATIN AMERICA: OPERATIONAL IMAGING SERVICES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 32 READ ANALYSIS SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 33 NORTH AMERICA: READ ANALYSIS SERVICES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 34 EUROPE: READ ANALYSIS SERVICES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 35 ASIA PACIFIC: READ ANALYSIS SERVICES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 36 LATIN AMERICA: READ ANALYSIS SERVICES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 37 SYSTEM AND TECHNICAL SUPPORT SERVICES MARKET, BY REGION,
2022–2029 (USD MILLION)
TABLE 38 NORTH AMERICA: SYSTEM AND TECHNICAL SUPPORT SERVICES MARKET,
BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 39 EUROPE: SYSTEM AND TECHNICAL SUPPORT SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 40 ASIA PACIFIC: SYSTEM AND TECHNICAL SUPPORT SERVICES MARKET,
BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 41 LATIN AMERICA: SYSTEM AND TECHNICAL SUPPORT SERVICES MARKET,
BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 42 TRIAL DESIGN AND CONSULTING SERVICES MARKET, BY REGION,
2022–2029 (USD MILLION)
TABLE 43 NORTH AMERICA: TRIAL DESIGN AND CONSULTING SERVICES MARKET,
BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 44 EUROPE: TRIAL DESIGN AND CONSULTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 45 ASIA PACIFIC: TRIAL DESIGN AND CONSULTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 46 LATIN AMERICA: TRIAL DESIGN AND CONSULTING SERVICES MARKET,
BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 47 CLINICAL TRIAL IMAGING SOFTWARE MARKET, BY REGION,
2022–2029 (USD MILLION)
TABLE 48 NORTH AMERICA: CLINICAL TRIAL IMAGING SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 49 EUROPE: CLINICAL TRIAL IMAGING SOFTWARE MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 50 ASIA PACIFIC: CLINICAL TRIAL IMAGING SOFTWARE MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 51 LATIN AMERICA: CLINICAL TRIAL IMAGING SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 52 CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2022–2029 (USD MILLION)
TABLE 53 CLINICAL TRIAL IMAGING MARKET FOR COMPUTED TOMOGRAPHY, BY REGION, 2022–2029 (USD MILLION)
TABLE 54 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR COMPUTED TOMOGRAPHY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 55 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR COMPUTED TOMOGRAPHY,
BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 56 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR COMPUTED TOMOGRAPHY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 57 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR COMPUTED TOMOGRAPHY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 58 CLINICAL TRIAL IMAGING MARKET FOR MAGNETIC RESONANCE IMAGING,
BY REGION, 2022–2029 (USD MILLION)
TABLE 59 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 60 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 61 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 62 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 63 CLINICAL TRIAL IMAGING MARKET FOR ULTRASOUND, BY REGION,
2022–2029 (USD MILLION)
TABLE 64 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR ULTRASOUND,
BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 65 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR ULTRASOUND, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 66 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR ULTRASOUND, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 67 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR ULTRASOUND,
BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 68 CLINICAL TRIAL IMAGING MARKET FOR POSITRON EMISSION TOMOGRAPHY,
BY REGION, 2022–2029 (USD MILLION)
TABLE 69 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 70 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 71 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 72 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 73 CLINICAL TRIAL IMAGING MARKET FOR X-RAY, BY REGION,
2022–2029 (USD MILLION)
TABLE 74 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR X-RAY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 75 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR X-RAY, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 76 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR X-RAY, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 77 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR X-RAY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 78 CLINICAL TRIAL IMAGING MARKET FOR OTHER MODALITIES, BY REGION,
2022–2029 (USD MILLION)
TABLE 79 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR OTHER MODALITIES,
BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 80 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR OTHER MODALITIES,
BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 81 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR OTHER MODALITIES,
BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 82 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR OTHER MODALITIES,
BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 83 CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA,
2022–2029 (USD MILLION)
TABLE 84 CLINICAL TRIAL IMAGING MARKET FOR ONCOLOGY, BY REGION,
2022–2029 (USD MILLION)
TABLE 85 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR ONCOLOGY,
BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 86 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR ONCOLOGY, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 87 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR ONCOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 88 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR ONCOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 89 CLINICAL TRIAL IMAGING MARKET FOR INFECTIOUS DISEASES, BY REGION, 2022–2029 (USD MILLION)
TABLE 90 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR INFECTIOUS DISEASES BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 91 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 92 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR INFECTIOUS DISEASES
BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 93 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR INFECTIOUS DISEASES
BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 94 CLINICAL TRIAL IMAGING MARKET FOR NEUROLOGY, BY REGION,
2022–2029 (USD MILLION)
TABLE 95 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR NEUROLOGY,
BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 96 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR NEUROLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 97 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR NEUROLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 98 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR NEUROLOGY,
BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 99 CLINICAL TRIAL IMAGING MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY REGION, 2022–2029 (USD MILLION)
TABLE 100 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 101 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 102 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 103 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 104 CLINICAL TRIAL IMAGING MARKET FOR ENDOCRINOLOGY, BY REGION,
2022–2029 (USD MILLION)
TABLE 105 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR ENDOCRINOLOGY,
BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 106 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 107 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR ENDOCRINOLOGY,
BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 108 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR ENDOCRINOLOGY,
BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 109 CLINICAL TRIAL IMAGING MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2022–2029 (USD MILLION)
TABLE 110 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 111 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 112 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 113 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 114 CLINICAL TRIAL IMAGING MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2022–2029 (USD MILLION)
TABLE 115 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 116 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR OTHER THERAPEUTIC AREAS,
BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 117 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 118 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 119 CLINICAL TRIAL IMAGING MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 120 CLINICAL TRIAL IMAGING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022–2029 (USD MILLION)
TABLE 121 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 122 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 123 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 124 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 125 CLINICAL TRIAL IMAGING MARKET FOR MEDICAL DEVICE MANUFACTURERS,
BY REGION, 2022–2029 (USD MILLION)
TABLE 126 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR MEDICAL DEVICE MANUFACTURERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 127 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR MEDICAL DEVICE MANUFACTURERS BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 128 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR MEDICAL DEVICE MANUFACTURERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 129 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR MEDICAL DEVICE MANUFACTURERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 130 CLINICAL TRIAL IMAGING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2022–2029 (USD MILLION)
TABLE 131 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 132 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 133 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 134 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 135 CLINICAL TRIAL IMAGING MARKET FOR ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2022–2029 (USD MILLION)
TABLE 136 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 137 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 138 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 139 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 140 CLINICAL TRIAL IMAGING MARKET FOR OTHER END USERS, BY REGION,
2022–2029 (USD MILLION)
TABLE 141 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR OTHER END USERS,
BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 142 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 143 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR OTHER END USERS,
BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 144 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR OTHER END USERS,
BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 145 CLINICAL TRIAL IMAGING MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 146 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 147 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2022–2029 (USD MILLION)
TABLE 148 NORTH AMERICA: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE,
2022–2029 (USD MILLION)
TABLE 149 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2022–2029 (USD MILLION)
TABLE 150 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 151 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2022–2029 (USD MILLION)
TABLE 152 NORTH AMERICA: KEY MACROINDICATORS
TABLE 153 US: LIST OF PRODUCT APPROVALS BY KEY PLAYERS, 2020–2023
TABLE 154 US: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE,
2022–2029 (USD MILLION)
TABLE 155 US: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE,
2022–2029 (USD MILLION)
TABLE 156 US: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2022–2029 (USD MILLION)
TABLE 157 US: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA,
2022–2029 (USD MILLION)
TABLE 158 US: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 159 CANADA: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE,
2022–2029 (USD MILLION)
TABLE 160 CANADA: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE,
2022–2029 (USD MILLION)
TABLE 161 CANADA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2022–2029 (USD MILLION)
TABLE 162 CANADA: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA,
2022–2029 (USD MILLION)
TABLE 163 CANADA: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2022–2029 (USD MILLION)
TABLE 164 EUROPE: CLINICAL TRIAL IMAGING MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 165 EUROPE: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE,
2022–2029 (USD MILLION)
TABLE 166 EUROPE: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE,
2022–2029 (USD MILLION)
TABLE 167 EUROPE: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2022–2029 (USD MILLION)
TABLE 168 EUROPE: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA,
2022–2029 (USD MILLION)
TABLE 169 EUROPE: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2022–2029 (USD MILLION)
TABLE 170 EUROPE: KEY MACROINDICATORS
TABLE 171 GERMANY: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE,
2022–2029 (USD MILLION)
TABLE 172 GERMANY: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE,
2022–2029 (USD MILLION)
TABLE 173 GERMANY: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2022–2029 (USD MILLION)
TABLE 174 GERMANY: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA,
2022–2029 (USD MILLION)
TABLE 175 GERMANY: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2022–2029 (USD MILLION)
TABLE 176 UK: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE,
2022–2029 (USD MILLION)
TABLE 177 UK: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE,
2022–2029 (USD MILLION)
TABLE 178 UK: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2022–2029 (USD MILLION)
TABLE 179 UK: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA,
2022–2029 (USD MILLION)
TABLE 180 UK: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 181 FRANCE: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE,
2022–2029 (USD MILLION)
TABLE 182 FRANCE: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE,
2022–2029 (USD MILLION)
TABLE 183 FRANCE: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2022–2029 (USD MILLION)
TABLE 184 FRANCE: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA,
2022–2029 (USD MILLION)
TABLE 185 FRANCE: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2022–2029 (USD MILLION)
TABLE 186 ITALY: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE,
2022–2029 (USD MILLION)
TABLE 187 ITALY: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE,
2022–2029 (USD MILLION)
TABLE 188 ITALY: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2022–2029 (USD MILLION)
TABLE 189 ITALY: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA,
2022–2029 (USD MILLION)
TABLE 190 ITALY: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2022–2029 (USD MILLION)
TABLE 191 SPAIN: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE,
2022–2029 (USD MILLION)
TABLE 192 SPAIN: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE,
2022–2029 (USD MILLION)
TABLE 193 SPAIN: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2022–2029 (USD MILLION)
TABLE 194 SPAIN: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA,
2022–2029 (USD MILLION)
TABLE 195 SPAIN: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2022–2029 (USD MILLION)
TABLE 196 REST OF EUROPE: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2022–2029(USD MILLION)
TABLE 197 REST OF EUROPE: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE,
2022–2029 (USD MILLION)
TABLE 198 REST OF EUROPE: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2022–2029 (USD MILLION)
TABLE 199 REST OF EUROPE: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 200 REST OF EUROPE: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2022–2029 (USD MILLION)
TABLE 201 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 202 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2022–2029 (USD MILLION)
TABLE 203 ASIA PACIFIC: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE,
2022–2029 (USD MILLION)
TABLE 204 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2022–2029 (USD MILLION)
TABLE 205 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA,
2022–2029 (USD MILLION)
TABLE 206 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2022–2029 (USD MILLION)
TABLE 207 ASIA PACIFIC: KEY MACROINDICATORS
TABLE 208 CHINA: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE,
2022–2029 (USD MILLION)
TABLE 209 CHINA: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE,
2022–2029 (USD MILLION)
TABLE 210 CHINA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2022–2029 (USD MILLION)
TABLE 211 CHINA: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA,
2022–2029 (USD MILLION)
TABLE 212 CHINA: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2022–2029 (USD MILLION)
TABLE 213 JAPAN: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE,
2022–2029 (USD MILLION)
TABLE 214 JAPAN: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE,
2022–2029 (USD MILLION)
TABLE 215 JAPAN: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2022–2029 (USD MILLION)
TABLE 216 JAPAN: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA,
2022–2029 (USD MILLION)
TABLE 217 JAPAN: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2022–2029 (USD MILLION)
TABLE 218 INDIA: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE,
2022–2029 (USD MILLION)
TABLE 219 INDIA: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE,
2022–2029 (USD MILLION)
TABLE 220 INDIA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2022–2029 (USD MILLION)
TABLE 221 INDIA: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA,
2022–2029 (USD MILLION)
TABLE 222 INDIA: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2022–2029 (USD MILLION)
TABLE 223 REST OF ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2022–2029 (USD MILLION)
TABLE 224 REST OF ASIA PACIFIC: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 225 REST OF ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2022–2029 (USD MILLION)
TABLE 226 REST OF ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 227 REST OF ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2022–2029 (USD MILLION)
TABLE 228 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 229 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2022–2029 (USD MILLION)
TABLE 230 LATIN AMERICA: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE,
2022–2029 (USD MILLION)
TABLE 231 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2022–2029 (USD MILLION)
TABLE 232 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 233 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2022–2029 (USD MILLION)
TABLE 234 LATIN AMERICA: KEY MACROINDICATORS
TABLE 235 BRAZIL: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE,
2022–2029 (USD MILLION)
TABLE 236 BRAZIL: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE,
2022–2029 (USD MILLION)
TABLE 237 BRAZIL: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2022–2029 (USD MILLION)
TABLE 238 BRAZIL: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA,
2022–2029 (USD MILLION)
TABLE 239 BRAZIL: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2022–2029 (USD MILLION)
TABLE 240 MEXICO: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE,
2022–2029 (USD MILLION)
TABLE 241 MEXICO: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE,
2022–2029 (USD MILLION)
TABLE 242 MEXICO: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2022–2029 (USD MILLION)
TABLE 243 MEXICO: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA,
2022–2029 (USD MILLION)
TABLE 244 MEXICO: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2022–2029 (USD MILLION)
TABLE 245 REST OF LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2022–2029 (USD MILLION)
TABLE 246 REST OF LATIN AMERICA: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 247 REST OF LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2022–2029 (USD MILLION)
TABLE 248 REST OF LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 249 REST OF LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 250 MIDDLE EAST & AFRICA: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2022–2029 (USD MILLION)
TABLE 251 MIDDLE EAST & AFRICA: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 252 MIDDLE EAST & AFRICA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2022–2029 (USD MILLION)
TABLE 253 MIDDLE EAST & AFRICA: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 254 MIDDLE EAST & AFRICA: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2022–2029 (USD MILLION)
TABLE 255 MIDDLE EAST & AFRICA: KEY MACROINDICATORS
TABLE 256 GCC COUNTRIES: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2022–2029 (USD MILLION)
TABLE 257 GCC COUNTRIES: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE,
2022–2029 (USD MILLION)
TABLE 258 GCC COUNTRIES: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2022–2029 (USD MILLION)
TABLE 259 GCC COUNTRIES: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 260 GCC COUNTRIES: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2022–2029 (USD MILLION)
TABLE 261 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN CLINICAL TRIAL IMAGING MARKET
TABLE 262 CLINICAL TRIAL IMAGING MARKET: DEGREE OF COMPETITION
TABLE 263 CLINICAL TRIAL IMAGING MARKET: SERVICE & SOFTWARE FOOTPRINT
TABLE 264 CLINICAL TRIAL IMAGING MARKET: THERAPEUTIC AREA FOOTPRINT
TABLE 265 CLINICAL TRIAL IMAGING MARKET: REGION FOOTPRINT
TABLE 266 CLINICAL TRIAL IMAGING MARKET: DETAILED LIST OF KEY STARTUPS/SMES
TABLE 267 CLINICAL TRIAL IMAGING MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUP/SME PLAYERS
TABLE 268 CLINICAL TRIAL IMAGING MARKET: SERVICE AND SOLUTION LAUNCHES AND REGULATORY APPROVALS, JANUARY 2020–AUGUST 2024
TABLE 269 CLINICAL TRIAL IMAGING MARKET: DEALS, JANUARY 2020–AUGUST 2024
TABLE 270 ICON PLC: COMPANY OVERVIEW
TABLE 271 ICON PLC: SERVICES/SOLUTIONS OFFERED
TABLE 272 ICON PLC: SOLUTION LAUNCHES, JANUARY 2020–AUGUST 2024
TABLE 273 ICON PLC: DEALS, JANUARY 2020–AUGUST 2024
TABLE 274 MEDPACE: COMPANY OVERVIEW
TABLE 275 MEDPACE: SERVICES/SOLUTIONS OFFERED
TABLE 276 CLARIO: COMPANY OVERVIEW
TABLE 277 CLARIO: SERVICES/SOLUTIONS OFFERED
TABLE 278 CLARIO: SOLUTION LAUNCHES, JANUARY 2020–AUGUST 2024
TABLE 279 CLARIO: DEALS, JANUARY 2020–AUGUST 2024
TABLE 280 IXICO PLC: COMPANY OVERVIEW
TABLE 281 IXICO PLC: SERVICES/SOLUTIONS OFFERED
TABLE 282 IXICO PLC: DEALS, JANUARY 2020–AUGUST 2024
TABLE 283 IXICO PLC: OTHER DEVELOPMENTS, JANUARY 2020–AUGUST 2024
TABLE 284 RESONANCE HEALTH LTD.: COMPANY OVERVIEW
TABLE 285 RESONANCE HEALTH LTD.: SERVICES/SOLUTIONS OFFERED
TABLE 286 RESONANCE HEALTH LTD.: SERVICE LAUNCHES AND REGULATORY APPROVALS, JANUARY 2020–AUGUST 2024
TABLE 287 RESONANCE HEALTH LTD.: DEALS, JANUARY 2020–AUGUST 2024
TABLE 288 RADIANT SAGE: COMPANY OVERVIEW
TABLE 289 RADIANT SAGE: SERVICES/SOLUTIONS OFFERED
TABLE 290 WCG CLINICAL: COMPANY OVERVIEW
TABLE 291 WCG CLINICAL: SERVICES/SOLUTIONS OFFERED
TABLE 292 WCG CLINICAL: DEALS, JANUARY 2021–AUGUST 2024
TABLE 293 CARDIOVASCULAR IMAGING TECHNOLOGIES: COMPANY OVERVIEW
TABLE 294 CARDIOVASCULAR IMAGING TECHNOLOGIES: SERVICES/SOLUTIONS OFFERED
TABLE 295 MEDICAL METRICS, INC.: COMPANY OVERVIEW
TABLE 296 PRISM CLINICAL IMAGING: COMPANY OVERVIEW
TABLE 297 BOSTON IMAGING CORE LAB: COMPANY OVERVIEW
TABLE 298 ANAGRAM 4 CLINICAL TRIALS: COMPANY OVERVIEW
TABLE 299 VOIANT: COMPANY OVERVIEW
TABLE 300 CALYX: COMPANY OVERVIEW
TABLE 301 BIOSPECTIVE INC.: COMPANY OVERVIEW
TABLE 302 PROSCAN IMAGING: COMPANY OVERVIEW
TABLE 303 MICRON, INC.: COMPANY OVERVIEW
TABLE 304 IMAGING ENDPOINTS: COMPANY OVERVIEW
TABLE 305 PERSPECTUM: COMPANY OVERVIEW
TABLE 306 PHARMTRACE: COMPANY OVERVIEW
TABLE 307 NAVITAS LIFE SCIENCES: COMPANY OVERVIEW
TABLE 308 MEDIAN TECHNOLOGIES: COMPANY OVERVIEW
TABLE 309 INVICRO, LLC: COMPANY OVERVIEW
TABLE 310 IMAGE CORE LAB: COMPANY OVERVIEW
TABLE 311 IMAGE ANALYSIS GROUP (IAG): COMPANY OVERVIEW
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 SEGMENTS CONSIDERED
1.3.2 INCLUSIONS AND EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.2 RESEARCH APPROACH
2.2.1 SECONDARY DATA
2.2.1.1 Key data from secondary sources
2.2.1.2 Objectives of secondary research
2.2.2 PRIMARY DATA
2.2.2.1 Objectives of primary research
2.2.2.2 Key data from primary sources
2.2.2.3 Key industry insights
2.2.2.4 Breakdown of primaries
2.3 MARKET SIZE ESTIMATION
2.3.1 BOTTOM-UP APPROACH
2.3.1.1 Company revenue estimation approach
2.3.1.2 Company presentations and primary interviews
2.3.1.3 Growth forecasts
2.3.1.4 CAGR projections
2.3.2 TOP-DOWN APPROACH
2.4 DATA TRIANGULATION
2.5 STUDY ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.7 RISK ASSESSMENT
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 CLINICAL TRIAL IMAGING MARKET OVERVIEW
4.2 CLINICAL TRIAL IMAGING MARKET SHARE, BY SERVICE & SOFTWARE, 2024 VS. 2029
4.3 CLINICAL TRIAL IMAGING MARKET SHARE, BY MODALITY, 2024 VS. 2029
4.4 CLINICAL TRIAL IMAGING MARKET SHARE, BY THERAPEUTIC AREA, 2024 VS. 2029
4.5 CLINICAL TRIAL IMAGING MARKET SHARE, BY END USER, 2024 VS. 2029
4.6 CLINICAL TRIAL IMAGING MARKET: REGIONAL GROWTH OPPORTUNITIES
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Increasing R&D spending in pharmaceutical and biotechnology companies
5.2.1.2 Rising number of clinical trials in medical research
5.2.1.3 Growth in pharmaceutical and biotechnology industries
5.2.1.4 Increasing number of contract research organizations
5.2.2 RESTRAINTS
5.2.2.1 High implementation cost of imaging systems
5.2.3 OPPORTUNITIES
5.2.3.1 Growth opportunities in emerging economies
5.2.3.2 Development of innovative imaging modalities, contrast agents, molecular probes, and radiopharmaceuticals
5.2.4 CHALLENGES
5.2.4.1 High cost of clinical trials
5.3 PRICING ANALYSIS
5.3.1 INDICATIVE PRICING ANALYSIS FOR CLINICAL TRIAL IMAGING SERVICES & SOFTWARE, 2021–2023
5.4 PATENT ANALYSIS
5.4.1 LIST OF MAJOR PATENTS, 2022–2023
5.5 TRADE ANALYSIS
5.5.1 TRADE ANALYSIS FOR X-RAY APPARATUS (HS CODE 9022)
5.5.1.1 Import data for X-ray apparatus
5.5.1.2 Export data for X-ray apparatus
5.5.2 TRADE ANALYSIS FOR CT APPARATUS (HS CODE 902212)
5.5.2.1 Import data for CT apparatus
5.5.2.2 Export data for CT apparatus
5.6 VALUE CHAIN ANALYSIS
5.7 SUPPLY CHAIN ANALYSIS
5.8 ECOSYSTEM ANALYSIS
5.8.1 ROLE IN ECOSYSTEM
5.9 PORTER’S FIVE FORCES ANALYSIS
5.9.1 THREAT OF NEW ENTRANTS
5.9.2 THREAT OF SUBSTITUTES
5.9.3 BARGAINING POWER OF BUYERS
5.9.4 BARGAINING POWER OF SUPPLIERS
5.9.5 INTENSITY OF COMPETITIVE RIVALRY
5.10 KEY STAKEHOLDERS AND BUYING CRITERIA
5.10.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.10.2 KEY BUYING CRITERIA
5.11 REGULATORY ANALYSIS
5.11.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.12 KEY CONFERENCES AND EVENTS IN 2023–2024
5.13 TECHNOLOGY ANALYSIS
5.13.1 KEY TECHNOLOGIES
5.13.1.1 CT and MRI
5.13.2 COMPLEMENTARY TECHNOLOGIES
5.13.2.1 Ultrasound
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.15 CASE STUDY ANALYSIS
5.15.1 REVIEW OF CT FINDINGS AND HISTOPATHOLOGICAL CHARACTERISTICS OF PRIMARY LIVER CARCINOSARCOMA
5.16 IMPACT OF AI/GENERATIVE AI ON CLINICAL TRIAL IMAGING MARKET
6 CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE
6.1 INTRODUCTION
6.2 SERVICES
6.2.1 OPERATIONAL IMAGING SERVICES
6.2.1.1 Rising number of CROs and growing pharmaceutical industry to drive market
6.2.2 READ ANALYSIS SERVICES
6.2.2.1 Increasing number of clinical trials and rising R&D spending to support market growth
6.2.3 SYSTEM AND TECHNICAL SUPPORT SERVICES
6.2.3.1 Need for continuous technical support to propel segment growth
6.2.4 TRIAL DESIGN AND CONSULTING SERVICES
6.2.4.1 High R&D spending and favorable government initiatives for clinical trials to fuel market growth
6.3 SOFTWARE
6.3.1 NEED FOR HIGHLY EFFICIENT AND COST-EFFECTIVE CLINICAL OPERATIONS SOFTWARE TO FAVOR MARKET GROWTH
7 CLINICAL TRIAL IMAGING MARKET, BY MODALITY
7.1 INTRODUCTION
7.2 COMPUTED TOMOGRAPHY
7.2.1 HIGHER CONTRAST IMAGE AND QUICKER TEST RESULTS TO AUGMENT SEGMENT GROWTH
7.3 MAGNETIC RESONANCE IMAGING
7.3.1 GREATER OBJECTIVITY, SENSITIVITY, AND REPRODUCIBILITY TO PROPEL MARKET GROWTH
7.4 ULTRASOUND
7.4.1 COST-EFFECTIVENESS AND EASE OF USE TO FUEL MARKET GROWTH
7.5 POSITRON EMISSION TOMOGRAPHY
7.5.1 ABILITY TO ASSESS PHARMACOKINETIC AND PHARMACODYNAMIC EVENTS IN HUMANS AND ANIMALS TO BOOST MARKET GROWTH
7.6 X-RAY
7.6.1 LOW SCANNING COST AND TECHNOLOGICAL ADVANCEMENTS TO FAVOR MARKET GROWTH
7.7 OTHER MODALITIES
8 CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA
8.1 INTRODUCTION
8.2 ONCOLOGY
8.2.1 GROWING INCIDENCE OF CANCER AND INCREASING R&D INVESTMENTS BY PHARMA COMPANIES TO AID MARKET GROWTH
8.3 INFECTIOUS DISEASES
8.3.1 RISING DRUG DISCOVERY ACTIVITY AND GROWING DEMAND FOR THERAPEUTICS TO SPUR MARKET GROWTH
8.4 NEUROLOGY
8.4.1 HIGH RESEARCH INVESTMENTS FOR NEUROLOGIC DRUGS TO PROPEL MARKET GROWTH
8.5 CARDIOVASCULAR SYSTEM DISORDERS
8.5.1 HIGH MORTALITY RATE AND COMPLEX CLINICAL TRIAL PROCEDURES TO AUGMENT MARKET GROWTH
8.6 ENDOCRINOLOGY
8.6.1 RISING PREVALENCE OF DIABETES AND INCREASING RESEARCH FUNDING FOR METABOLIC DISORDERS TO DRIVE MARKET
8.7 IMMUNOLOGICAL DISORDERS
8.7.1 WIDE PREVALENCE OF ALLERGIES, ASTHMA, AND AUTOIMMUNE DISEASES TO SUPPORT MARKET GROWTH
8.8 OTHER THERAPEUTIC AREAS
9 CLINICAL TRIAL IMAGING MARKET, BY END USER
9.1 INTRODUCTION
9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
9.2.1 HIGH R&D BUDGETS AND FAVORABLE GOVERNMENT INITIATIVES TO SUPPORT MARKET GROWTH
9.3 MEDICAL DEVICE MANUFACTURERS
9.3.1 HIGH SPENDING ON R&D AND CLINICAL TRIALS TO SUPPORT MARKET GROWTH
9.4 CONTRACT RESEARCH ORGANIZATIONS
9.4.1 INCREASING TREND OF OUTSOURCING AND GROWING PATIENT POPULATION IN EMERGING ECONOMIES TO AID MARKET GROWTH
9.5 ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES
9.5.1 RISING RESEARCH FUNDING AND INCREASING GOVERNMENT SUPPORT FOR CLINICAL TRIALS TO BOOST MARKET GROWTH
9.6 OTHER END USERS
10 CLINICAL TRIAL IMAGING MARKET, BY REGION
10.1 INTRODUCTION
10.2 NORTH AMERICA
10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
10.2.2 US
10.2.2.1 US to dominate North American clinical trial imaging market during study period
10.2.3 CANADA
10.2.3.1 Increase in per capita healthcare spending to augment market growth
10.3 EUROPE
10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
10.3.2 GERMANY
10.3.2.1 Strong medical technology infrastructure and increased funding for biomedical research to augment market growth
10.3.3 UK
10.3.3.1 Increased R&D investments and high per capita healthcare expenditure to augment market growth
10.3.4 FRANCE
10.3.4.1 Developed generics market and favorable government healthcare policies to support market growth
10.3.5 ITALY
10.3.5.1 Increasing number of drug approvals and rising investments in clinical trials to drive market
10.3.6 SPAIN
10.3.6.1 Increased biologics production and improved healthcare infrastructure to aid market growth
10.3.7 REST OF EUROPE
10.4 ASIA PACIFIC
10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
10.4.2 CHINA
10.4.2.1 Favorable government regulations and presence of large target patient population to boost market growth
10.4.3 JAPAN
10.4.3.1 Increasing geriatric population and rising healthcare expenditure to favor market growth
10.4.4 INDIA
10.4.4.1 Increased government focus on developing advanced healthcare infrastructure to augment market growth
10.4.5 REST OF ASIA PACIFIC
10.5 LATIN AMERICA
10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
10.5.2 BRAZIL
10.5.2.1 Increasing investments in biopharmaceutical research to propel market growth
10.5.3 MEXICO
10.5.3.1 Developed pharmaceutical and biotechnology industry and high demand for personalized medicines to aid market growth
10.5.4 REST OF LATIN AMERICA
10.6 MIDDLE EAST & AFRICA
10.6.1 INCREASED FUNDING AND COLLABORATIONS IN RESEARCH SECTOR TO DRIVE MARKET
10.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
10.7 GCC COUNTRIES
10.7.1 INCREASING RESEARCH ACTIVITIES AND GROWING BIOTECHNOLOGY INDUSTRY TO SPUR MARKET GROWTH
10.7.2 MACROECONOMIC OUTLOOK FOR GCC COUNTRIES
11 COMPETITIVE LANDSCAPE
11.1 INTRODUCTION
11.2 KEY PLAYER STRATEGY/RIGHT TO WIN
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN CLINICAL TRIAL IMAGING MARKET
11.3 REVENUE ANALYSIS, 2021–2023
11.4 MARKET SHARE ANALYSIS, 2023
11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS (2023)
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE PLAYERS
11.5.4 PARTICIPANTS
11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
11.5.5.1 Company footprint
11.5.5.2 Service & software footprint
11.5.5.3 Therapeutic area footprint
11.5.5.4 Region footprint
11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
11.6.1 PROGRESSIVE COMPANIES
11.6.2 RESPONSIVE COMPANIES
11.6.3 DYNAMIC COMPANIES
11.6.4 STARTING BLOCKS
11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
11.7 COMPANY VALUATION AND FINANCIAL METRICS
11.8 COMPETITIVE SCENARIO
11.8.1 SERVICE AND SOLUTION LAUNCHES AND REGULATORY APPROVALS
11.8.2 DEALS
12 COMPANY PROFILES
12.1 KEY PLAYERS
12.1.1 ICON PLC
12.1.1.1 Business overview
12.1.1.2 Services/Solutions offered
12.1.1.3 Recent developments
12.1.1.3.1 Solution launches
12.1.1.3.2 Deals
12.1.1.4 MnM view
12.1.1.4.1 Key strengths
12.1.1.4.2 Strategic choices
12.1.1.4.3 Weaknesses and competitive threats
12.1.2 MEDPACE
12.1.2.1 Business overview
12.1.2.2 Services/Solutions offered
12.1.2.3 MnM view
12.1.2.3.1 Key strengths
12.1.2.3.2 Strategic choices
12.1.2.3.3 Weaknesses and competitive threats
12.1.3 CLARIO
12.1.3.1 Business overview
12.1.3.2 Services/Solutions offered
12.1.3.3 Recent developments
12.1.3.3.1 Solution launches
12.1.3.3.2 Deals
12.1.3.4 MnM view
12.1.3.4.1 Key strengths
12.1.3.4.2 Strategic choices
12.1.3.4.3 Weaknesses and competitive threats
12.1.4 IXICO PLC
12.1.4.1 Business overview
12.1.4.2 Services/Solutions offered
12.1.4.3 Recent developments
12.1.4.3.1 Deals
12.1.4.3.2 Other developments
12.1.5 RESONANCE HEALTH LTD.
12.1.5.1 Business overview
12.1.5.2 Services/Solutions offered
12.1.5.3 Recent developments
12.1.5.3.1 Service launches and regulatory approvals
12.1.5.3.2 Deals
12.1.6 RADIANT SAGE
12.1.6.1 Business overview
12.1.6.2 Services/Solutions offered
12.1.7 WCG CLINICAL
12.1.7.1 Business overview
12.1.7.2 Services/Solutions offered
12.1.7.3 Recent developments
12.1.7.3.1 Deals
12.1.8 CARDIOVASCULAR IMAGING TECHNOLOGIES
12.1.8.1 Business overview
12.1.8.2 Services/Solutions offered
12.2 OTHER PLAYERS
12.2.1 MEDICAL METRICS, INC.
12.2.2 PRISM CLINICAL IMAGING
12.2.3 BOSTON IMAGING CORE LAB
12.2.4 ANAGRAM 4 CLINICAL TRIALS
12.2.5 VOIANT
12.2.6 CALYX
12.2.7 BIOSPECTIVE INC.
12.2.8 PROSCAN IMAGING
12.2.9 MICRON, INC.
12.2.10 IMAGING ENDPOINTS
12.2.11 PERSPECTUM
12.2.12 PHARMTRACE
12.2.13 NAVITAS LIFE SCIENCES
12.2.14 MEDIAN TECHNOLOGIES
12.2.15 INVICRO, LLC
12.2.16 IMAGE CORE LAB
12.2.17 IMAGE ANALYSIS GROUP (IAG)
13 APPENDIX
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 CUSTOMIZATION OPTIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
TABLE 1 CLINICAL TRIAL IMAGING MARKET: INCLUSIONS AND EXCLUSIONS
TABLE 2 CLINICAL TRIAL IMAGING MARKET: KEY DATA FROM PRIMARY SOURCES
TABLE 3 CLINICAL TRIAL IMAGING MARKET: RISK ASSESSMENT ANALYSIS
TABLE 4 INDICATIVE SELLING PRICE TREND FOR CLINICAL TRIAL IMAGING SERVICES & SOFTWARE, 2021–2023
TABLE 5 CLINICAL TRIAL IMAGING MARKET: LIST OF KEY PATENTS,
JANUARY 2022–DECEMBER 2023
TABLE 6 IMPORT DATA FOR X-RAY APPARATUS (HS CODE 9022), BY COUNTRY,
2018–2022 (USD MILLION)
TABLE 7 EXPORT DATA FOR X-RAY APPARATUS (HS CODE 9022), BY COUNTRY,
2018–2022 (USD MILLION)
TABLE 8 IMPORT DATA FOR CT APPARATUS (HS CODE 902212), BY COUNTRY,
2018–2022 (USD MILLION)
TABLE 9 EXPORT DATA FOR CT APPARATUS (HS CODE 902212), BY COUNTRY,
2018–2022 (USD MILLION)
TABLE 10 CLINICAL TRIAL IMAGING MARKET: ROLE IN ECOSYSTEM
TABLE 11 CLINICAL TRIAL IMAGING MARKET: IMPACT OF PORTER’S FIVE FORCES
TABLE 12 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS
TABLE 13 KEY BUYING CRITERIA FOR MAJOR END USERS
TABLE 14 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS
TABLE 15 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 16 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS
TABLE 17 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS
TABLE 18 MIDDLE EAST & AFRICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 19 CLINICAL TRIAL IMAGING MARKET: DETAILED LIST OF KEY CONFERENCES AND EVENTS, JANUARY 2023–DECEMBER 2024
TABLE 20 CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE,
2022–2029 (USD MILLION)
TABLE 21 CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE,
2022–2029 (USD MILLION)
TABLE 22 CLINICAL TRIAL IMAGING SERVICES MARKET, BY REGION,
2022–2029 (USD MILLION)
TABLE 23 NORTH AMERICA: CLINICAL TRIAL IMAGING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 24 EUROPE: CLINICAL TRIAL IMAGING SERVICES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 25 ASIA PACIFIC: CLINICAL TRIAL IMAGING SERVICES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 26 LATIN AMERICA: CLINICAL TRIAL IMAGING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 27 OPERATIONAL IMAGING SERVICES MARKET, BY REGION,
2022–2029 (USD MILLION)
TABLE 28 NORTH AMERICA: OPERATIONAL IMAGING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 29 EUROPE: OPERATIONAL IMAGING SERVICES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 30 ASIA PACIFIC: OPERATIONAL IMAGING SERVICES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 31 LATIN AMERICA: OPERATIONAL IMAGING SERVICES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 32 READ ANALYSIS SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 33 NORTH AMERICA: READ ANALYSIS SERVICES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 34 EUROPE: READ ANALYSIS SERVICES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 35 ASIA PACIFIC: READ ANALYSIS SERVICES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 36 LATIN AMERICA: READ ANALYSIS SERVICES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 37 SYSTEM AND TECHNICAL SUPPORT SERVICES MARKET, BY REGION,
2022–2029 (USD MILLION)
TABLE 38 NORTH AMERICA: SYSTEM AND TECHNICAL SUPPORT SERVICES MARKET,
BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 39 EUROPE: SYSTEM AND TECHNICAL SUPPORT SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 40 ASIA PACIFIC: SYSTEM AND TECHNICAL SUPPORT SERVICES MARKET,
BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 41 LATIN AMERICA: SYSTEM AND TECHNICAL SUPPORT SERVICES MARKET,
BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 42 TRIAL DESIGN AND CONSULTING SERVICES MARKET, BY REGION,
2022–2029 (USD MILLION)
TABLE 43 NORTH AMERICA: TRIAL DESIGN AND CONSULTING SERVICES MARKET,
BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 44 EUROPE: TRIAL DESIGN AND CONSULTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 45 ASIA PACIFIC: TRIAL DESIGN AND CONSULTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 46 LATIN AMERICA: TRIAL DESIGN AND CONSULTING SERVICES MARKET,
BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 47 CLINICAL TRIAL IMAGING SOFTWARE MARKET, BY REGION,
2022–2029 (USD MILLION)
TABLE 48 NORTH AMERICA: CLINICAL TRIAL IMAGING SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 49 EUROPE: CLINICAL TRIAL IMAGING SOFTWARE MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 50 ASIA PACIFIC: CLINICAL TRIAL IMAGING SOFTWARE MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 51 LATIN AMERICA: CLINICAL TRIAL IMAGING SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 52 CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2022–2029 (USD MILLION)
TABLE 53 CLINICAL TRIAL IMAGING MARKET FOR COMPUTED TOMOGRAPHY, BY REGION, 2022–2029 (USD MILLION)
TABLE 54 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR COMPUTED TOMOGRAPHY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 55 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR COMPUTED TOMOGRAPHY,
BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 56 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR COMPUTED TOMOGRAPHY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 57 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR COMPUTED TOMOGRAPHY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 58 CLINICAL TRIAL IMAGING MARKET FOR MAGNETIC RESONANCE IMAGING,
BY REGION, 2022–2029 (USD MILLION)
TABLE 59 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 60 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 61 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 62 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 63 CLINICAL TRIAL IMAGING MARKET FOR ULTRASOUND, BY REGION,
2022–2029 (USD MILLION)
TABLE 64 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR ULTRASOUND,
BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 65 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR ULTRASOUND, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 66 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR ULTRASOUND, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 67 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR ULTRASOUND,
BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 68 CLINICAL TRIAL IMAGING MARKET FOR POSITRON EMISSION TOMOGRAPHY,
BY REGION, 2022–2029 (USD MILLION)
TABLE 69 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 70 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 71 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 72 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 73 CLINICAL TRIAL IMAGING MARKET FOR X-RAY, BY REGION,
2022–2029 (USD MILLION)
TABLE 74 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR X-RAY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 75 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR X-RAY, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 76 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR X-RAY, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 77 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR X-RAY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 78 CLINICAL TRIAL IMAGING MARKET FOR OTHER MODALITIES, BY REGION,
2022–2029 (USD MILLION)
TABLE 79 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR OTHER MODALITIES,
BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 80 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR OTHER MODALITIES,
BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 81 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR OTHER MODALITIES,
BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 82 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR OTHER MODALITIES,
BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 83 CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA,
2022–2029 (USD MILLION)
TABLE 84 CLINICAL TRIAL IMAGING MARKET FOR ONCOLOGY, BY REGION,
2022–2029 (USD MILLION)
TABLE 85 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR ONCOLOGY,
BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 86 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR ONCOLOGY, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 87 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR ONCOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 88 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR ONCOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 89 CLINICAL TRIAL IMAGING MARKET FOR INFECTIOUS DISEASES, BY REGION, 2022–2029 (USD MILLION)
TABLE 90 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR INFECTIOUS DISEASES BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 91 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 92 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR INFECTIOUS DISEASES
BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 93 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR INFECTIOUS DISEASES
BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 94 CLINICAL TRIAL IMAGING MARKET FOR NEUROLOGY, BY REGION,
2022–2029 (USD MILLION)
TABLE 95 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR NEUROLOGY,
BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 96 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR NEUROLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 97 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR NEUROLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 98 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR NEUROLOGY,
BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 99 CLINICAL TRIAL IMAGING MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY REGION, 2022–2029 (USD MILLION)
TABLE 100 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 101 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 102 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 103 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 104 CLINICAL TRIAL IMAGING MARKET FOR ENDOCRINOLOGY, BY REGION,
2022–2029 (USD MILLION)
TABLE 105 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR ENDOCRINOLOGY,
BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 106 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 107 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR ENDOCRINOLOGY,
BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 108 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR ENDOCRINOLOGY,
BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 109 CLINICAL TRIAL IMAGING MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2022–2029 (USD MILLION)
TABLE 110 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 111 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 112 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 113 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 114 CLINICAL TRIAL IMAGING MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2022–2029 (USD MILLION)
TABLE 115 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 116 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR OTHER THERAPEUTIC AREAS,
BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 117 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 118 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 119 CLINICAL TRIAL IMAGING MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 120 CLINICAL TRIAL IMAGING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022–2029 (USD MILLION)
TABLE 121 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 122 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 123 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 124 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 125 CLINICAL TRIAL IMAGING MARKET FOR MEDICAL DEVICE MANUFACTURERS,
BY REGION, 2022–2029 (USD MILLION)
TABLE 126 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR MEDICAL DEVICE MANUFACTURERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 127 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR MEDICAL DEVICE MANUFACTURERS BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 128 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR MEDICAL DEVICE MANUFACTURERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 129 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR MEDICAL DEVICE MANUFACTURERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 130 CLINICAL TRIAL IMAGING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2022–2029 (USD MILLION)
TABLE 131 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 132 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 133 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 134 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 135 CLINICAL TRIAL IMAGING MARKET FOR ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2022–2029 (USD MILLION)
TABLE 136 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 137 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 138 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 139 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 140 CLINICAL TRIAL IMAGING MARKET FOR OTHER END USERS, BY REGION,
2022–2029 (USD MILLION)
TABLE 141 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR OTHER END USERS,
BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 142 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 143 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR OTHER END USERS,
BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 144 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR OTHER END USERS,
BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 145 CLINICAL TRIAL IMAGING MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 146 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 147 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2022–2029 (USD MILLION)
TABLE 148 NORTH AMERICA: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE,
2022–2029 (USD MILLION)
TABLE 149 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2022–2029 (USD MILLION)
TABLE 150 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 151 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2022–2029 (USD MILLION)
TABLE 152 NORTH AMERICA: KEY MACROINDICATORS
TABLE 153 US: LIST OF PRODUCT APPROVALS BY KEY PLAYERS, 2020–2023
TABLE 154 US: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE,
2022–2029 (USD MILLION)
TABLE 155 US: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE,
2022–2029 (USD MILLION)
TABLE 156 US: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2022–2029 (USD MILLION)
TABLE 157 US: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA,
2022–2029 (USD MILLION)
TABLE 158 US: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 159 CANADA: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE,
2022–2029 (USD MILLION)
TABLE 160 CANADA: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE,
2022–2029 (USD MILLION)
TABLE 161 CANADA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2022–2029 (USD MILLION)
TABLE 162 CANADA: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA,
2022–2029 (USD MILLION)
TABLE 163 CANADA: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2022–2029 (USD MILLION)
TABLE 164 EUROPE: CLINICAL TRIAL IMAGING MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 165 EUROPE: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE,
2022–2029 (USD MILLION)
TABLE 166 EUROPE: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE,
2022–2029 (USD MILLION)
TABLE 167 EUROPE: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2022–2029 (USD MILLION)
TABLE 168 EUROPE: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA,
2022–2029 (USD MILLION)
TABLE 169 EUROPE: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2022–2029 (USD MILLION)
TABLE 170 EUROPE: KEY MACROINDICATORS
TABLE 171 GERMANY: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE,
2022–2029 (USD MILLION)
TABLE 172 GERMANY: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE,
2022–2029 (USD MILLION)
TABLE 173 GERMANY: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2022–2029 (USD MILLION)
TABLE 174 GERMANY: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA,
2022–2029 (USD MILLION)
TABLE 175 GERMANY: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2022–2029 (USD MILLION)
TABLE 176 UK: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE,
2022–2029 (USD MILLION)
TABLE 177 UK: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE,
2022–2029 (USD MILLION)
TABLE 178 UK: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2022–2029 (USD MILLION)
TABLE 179 UK: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA,
2022–2029 (USD MILLION)
TABLE 180 UK: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 181 FRANCE: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE,
2022–2029 (USD MILLION)
TABLE 182 FRANCE: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE,
2022–2029 (USD MILLION)
TABLE 183 FRANCE: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2022–2029 (USD MILLION)
TABLE 184 FRANCE: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA,
2022–2029 (USD MILLION)
TABLE 185 FRANCE: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2022–2029 (USD MILLION)
TABLE 186 ITALY: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE,
2022–2029 (USD MILLION)
TABLE 187 ITALY: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE,
2022–2029 (USD MILLION)
TABLE 188 ITALY: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2022–2029 (USD MILLION)
TABLE 189 ITALY: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA,
2022–2029 (USD MILLION)
TABLE 190 ITALY: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2022–2029 (USD MILLION)
TABLE 191 SPAIN: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE,
2022–2029 (USD MILLION)
TABLE 192 SPAIN: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE,
2022–2029 (USD MILLION)
TABLE 193 SPAIN: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2022–2029 (USD MILLION)
TABLE 194 SPAIN: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA,
2022–2029 (USD MILLION)
TABLE 195 SPAIN: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2022–2029 (USD MILLION)
TABLE 196 REST OF EUROPE: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2022–2029(USD MILLION)
TABLE 197 REST OF EUROPE: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE,
2022–2029 (USD MILLION)
TABLE 198 REST OF EUROPE: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2022–2029 (USD MILLION)
TABLE 199 REST OF EUROPE: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 200 REST OF EUROPE: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2022–2029 (USD MILLION)
TABLE 201 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 202 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2022–2029 (USD MILLION)
TABLE 203 ASIA PACIFIC: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE,
2022–2029 (USD MILLION)
TABLE 204 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2022–2029 (USD MILLION)
TABLE 205 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA,
2022–2029 (USD MILLION)
TABLE 206 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2022–2029 (USD MILLION)
TABLE 207 ASIA PACIFIC: KEY MACROINDICATORS
TABLE 208 CHINA: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE,
2022–2029 (USD MILLION)
TABLE 209 CHINA: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE,
2022–2029 (USD MILLION)
TABLE 210 CHINA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2022–2029 (USD MILLION)
TABLE 211 CHINA: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA,
2022–2029 (USD MILLION)
TABLE 212 CHINA: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2022–2029 (USD MILLION)
TABLE 213 JAPAN: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE,
2022–2029 (USD MILLION)
TABLE 214 JAPAN: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE,
2022–2029 (USD MILLION)
TABLE 215 JAPAN: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2022–2029 (USD MILLION)
TABLE 216 JAPAN: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA,
2022–2029 (USD MILLION)
TABLE 217 JAPAN: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2022–2029 (USD MILLION)
TABLE 218 INDIA: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE,
2022–2029 (USD MILLION)
TABLE 219 INDIA: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE,
2022–2029 (USD MILLION)
TABLE 220 INDIA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2022–2029 (USD MILLION)
TABLE 221 INDIA: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA,
2022–2029 (USD MILLION)
TABLE 222 INDIA: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2022–2029 (USD MILLION)
TABLE 223 REST OF ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2022–2029 (USD MILLION)
TABLE 224 REST OF ASIA PACIFIC: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 225 REST OF ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2022–2029 (USD MILLION)
TABLE 226 REST OF ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 227 REST OF ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2022–2029 (USD MILLION)
TABLE 228 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 229 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2022–2029 (USD MILLION)
TABLE 230 LATIN AMERICA: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE,
2022–2029 (USD MILLION)
TABLE 231 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2022–2029 (USD MILLION)
TABLE 232 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 233 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2022–2029 (USD MILLION)
TABLE 234 LATIN AMERICA: KEY MACROINDICATORS
TABLE 235 BRAZIL: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE,
2022–2029 (USD MILLION)
TABLE 236 BRAZIL: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE,
2022–2029 (USD MILLION)
TABLE 237 BRAZIL: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2022–2029 (USD MILLION)
TABLE 238 BRAZIL: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA,
2022–2029 (USD MILLION)
TABLE 239 BRAZIL: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2022–2029 (USD MILLION)
TABLE 240 MEXICO: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE,
2022–2029 (USD MILLION)
TABLE 241 MEXICO: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE,
2022–2029 (USD MILLION)
TABLE 242 MEXICO: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2022–2029 (USD MILLION)
TABLE 243 MEXICO: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA,
2022–2029 (USD MILLION)
TABLE 244 MEXICO: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2022–2029 (USD MILLION)
TABLE 245 REST OF LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2022–2029 (USD MILLION)
TABLE 246 REST OF LATIN AMERICA: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 247 REST OF LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2022–2029 (USD MILLION)
TABLE 248 REST OF LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 249 REST OF LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 250 MIDDLE EAST & AFRICA: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2022–2029 (USD MILLION)
TABLE 251 MIDDLE EAST & AFRICA: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 252 MIDDLE EAST & AFRICA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2022–2029 (USD MILLION)
TABLE 253 MIDDLE EAST & AFRICA: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 254 MIDDLE EAST & AFRICA: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2022–2029 (USD MILLION)
TABLE 255 MIDDLE EAST & AFRICA: KEY MACROINDICATORS
TABLE 256 GCC COUNTRIES: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2022–2029 (USD MILLION)
TABLE 257 GCC COUNTRIES: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE,
2022–2029 (USD MILLION)
TABLE 258 GCC COUNTRIES: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2022–2029 (USD MILLION)
TABLE 259 GCC COUNTRIES: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 260 GCC COUNTRIES: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2022–2029 (USD MILLION)
TABLE 261 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN CLINICAL TRIAL IMAGING MARKET
TABLE 262 CLINICAL TRIAL IMAGING MARKET: DEGREE OF COMPETITION
TABLE 263 CLINICAL TRIAL IMAGING MARKET: SERVICE & SOFTWARE FOOTPRINT
TABLE 264 CLINICAL TRIAL IMAGING MARKET: THERAPEUTIC AREA FOOTPRINT
TABLE 265 CLINICAL TRIAL IMAGING MARKET: REGION FOOTPRINT
TABLE 266 CLINICAL TRIAL IMAGING MARKET: DETAILED LIST OF KEY STARTUPS/SMES
TABLE 267 CLINICAL TRIAL IMAGING MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUP/SME PLAYERS
TABLE 268 CLINICAL TRIAL IMAGING MARKET: SERVICE AND SOLUTION LAUNCHES AND REGULATORY APPROVALS, JANUARY 2020–AUGUST 2024
TABLE 269 CLINICAL TRIAL IMAGING MARKET: DEALS, JANUARY 2020–AUGUST 2024
TABLE 270 ICON PLC: COMPANY OVERVIEW
TABLE 271 ICON PLC: SERVICES/SOLUTIONS OFFERED
TABLE 272 ICON PLC: SOLUTION LAUNCHES, JANUARY 2020–AUGUST 2024
TABLE 273 ICON PLC: DEALS, JANUARY 2020–AUGUST 2024
TABLE 274 MEDPACE: COMPANY OVERVIEW
TABLE 275 MEDPACE: SERVICES/SOLUTIONS OFFERED
TABLE 276 CLARIO: COMPANY OVERVIEW
TABLE 277 CLARIO: SERVICES/SOLUTIONS OFFERED
TABLE 278 CLARIO: SOLUTION LAUNCHES, JANUARY 2020–AUGUST 2024
TABLE 279 CLARIO: DEALS, JANUARY 2020–AUGUST 2024
TABLE 280 IXICO PLC: COMPANY OVERVIEW
TABLE 281 IXICO PLC: SERVICES/SOLUTIONS OFFERED
TABLE 282 IXICO PLC: DEALS, JANUARY 2020–AUGUST 2024
TABLE 283 IXICO PLC: OTHER DEVELOPMENTS, JANUARY 2020–AUGUST 2024
TABLE 284 RESONANCE HEALTH LTD.: COMPANY OVERVIEW
TABLE 285 RESONANCE HEALTH LTD.: SERVICES/SOLUTIONS OFFERED
TABLE 286 RESONANCE HEALTH LTD.: SERVICE LAUNCHES AND REGULATORY APPROVALS, JANUARY 2020–AUGUST 2024
TABLE 287 RESONANCE HEALTH LTD.: DEALS, JANUARY 2020–AUGUST 2024
TABLE 288 RADIANT SAGE: COMPANY OVERVIEW
TABLE 289 RADIANT SAGE: SERVICES/SOLUTIONS OFFERED
TABLE 290 WCG CLINICAL: COMPANY OVERVIEW
TABLE 291 WCG CLINICAL: SERVICES/SOLUTIONS OFFERED
TABLE 292 WCG CLINICAL: DEALS, JANUARY 2021–AUGUST 2024
TABLE 293 CARDIOVASCULAR IMAGING TECHNOLOGIES: COMPANY OVERVIEW
TABLE 294 CARDIOVASCULAR IMAGING TECHNOLOGIES: SERVICES/SOLUTIONS OFFERED
TABLE 295 MEDICAL METRICS, INC.: COMPANY OVERVIEW
TABLE 296 PRISM CLINICAL IMAGING: COMPANY OVERVIEW
TABLE 297 BOSTON IMAGING CORE LAB: COMPANY OVERVIEW
TABLE 298 ANAGRAM 4 CLINICAL TRIALS: COMPANY OVERVIEW
TABLE 299 VOIANT: COMPANY OVERVIEW
TABLE 300 CALYX: COMPANY OVERVIEW
TABLE 301 BIOSPECTIVE INC.: COMPANY OVERVIEW
TABLE 302 PROSCAN IMAGING: COMPANY OVERVIEW
TABLE 303 MICRON, INC.: COMPANY OVERVIEW
TABLE 304 IMAGING ENDPOINTS: COMPANY OVERVIEW
TABLE 305 PERSPECTUM: COMPANY OVERVIEW
TABLE 306 PHARMTRACE: COMPANY OVERVIEW
TABLE 307 NAVITAS LIFE SCIENCES: COMPANY OVERVIEW
TABLE 308 MEDIAN TECHNOLOGIES: COMPANY OVERVIEW
TABLE 309 INVICRO, LLC: COMPANY OVERVIEW
TABLE 310 IMAGE CORE LAB: COMPANY OVERVIEW
TABLE 311 IMAGE ANALYSIS GROUP (IAG): COMPANY OVERVIEW
